News | November 09, 2023
Biocon Biologics announces divestment of two non-core branded formulations
Total transaction value of the divestment is Rs. 3,660 million
Total transaction value of the divestment is Rs. 3,660 million
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Investment is additive to KKR’s existing health care growth strategy
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Subscribe To Our Newsletter & Stay Updated
